Adalimumab

• Description:

  Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α) .

• Product Name Alternative:

  Anti-Human TNF-alpha, Human Antibody

• UNSPSC:

  12352203

• Target:

  Bacterial; TNF Receptor

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Anti-infection; Apoptosis

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Adalimumab.html

• Purity:

  99.90

• Solubility:

  H2O

• Smiles:

  [Adalimumab]

• Molecular Weight:

  (145.43 kDa)

• References & Citations:

  [1]Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79 (2) :286-97.|[2]Oberoi R, et al. Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS One. 2016 Jul 28;11 (7) :e0160145.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Launched

• CAS Number:

  [331731-18-1]